Bio-Rad Laboratories Inc. Cl A

Bio-Rad Laboratories is a manufacturer and distributor of its own life science research and clinical diagnostics products. The company has two primary segments: Life Science, which is engaged in the life sciences market and develops, manufactures and markets reagents, apparatus and laboratory instruments; and Clinical Diagnostics, which designs, manufactures, sells and supports test systems, informatics systems, test kits and quality controls that serve clinical laboratories in the diagnostics market. The company sells its products and services to a client base comprised of scientific research, healthcare, education and government customers.
  • TickerBIO
  • ISINUS0905722072
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States
BIO Bio-Rad Laborat... (Health Care)

Thanks to a better fundamental star rating, BIO-RAD LABORATORIES sees ...

The independent financial analyst theScreener just awarded an improved star rating to BIO-RAD LABORATORIES (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date April 9, 2021, the closing price was USD 602.57 and its expected value was estimated at USD 582.39.

BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Laboratories, Inc. - June 2020 (LTM): Peer Snapshot

Peer Snapshot:  Bio-Rad Laboratories, Inc. - June 2020 (LTM) 9 September 2020 (in US millions) FYE Dec-18 FYE Dec-19 LTM Jun-20 FYE Dec-18 FYE Dec-19 LTM Jul-20 FYE Oct-18 FYE Oct-19 LTM Apr-20

BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Laboratories, Inc.: Update to credit analysis - Strong financi...

Bio-Rad will continue to operate with prudent financial policies and low financial leverage over the next 12-18 months despite coronavirus headwinds. But M&A could accelerate.

BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Laboratories, Inc. - March 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BIO Bio-Rad Laborat... (Health Care)

Moody's announces completion of a periodic review of ratings of Bio-Ra...

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc.. Global Credit Research- 15 May 2020. New York, May 15, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Bio-Rad Laboratories, Inc. and other ratings that are associated with the same analytical unit.

 PRESS RELEASE
BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Reports First Quarter 2018 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2018. First-quarter 2018 net sales were $551.5 million, an increase of 10.3 percent compared to $500.1 million reported for the first quarter of 2017. On a currency-neutral basis, quarterly sales increased 4.5 percent compared to the same period in 2017. First-quarter gross margin was 54.8 percent ...

 PRESS RELEASE
BIO Bio-Rad Laborat... (Health Care)

Bio-Rad to Report First-Quarter 2018 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2018 on Tuesday, May 8, 2018, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., Conference ID: 7876416. You may also listen to the co...

 PRESS RELEASE
BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Lat...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual due to the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year...

 PRESS RELEASE
BIO Bio-Rad Laborat... (Health Care)

Bio-Rad to Present at Barclays Global Healthcare Conference 2018 on Ma...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, at 3:50 PM (EST), at Loews Miami Beach Hotel, Florida. A link to the live webcast of the presentation is available in the Investor Relations area of our website atwww.bio...

 PRESS RELEASE
BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Reports Fourth-Quarter and Full-Year 2017 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017. Fourth-quarter 2017 net sales were $620.4 million, an increase of 8.6 percent compared to $571.5 million reported for the fourth quarter of 2016. On a currency-neutral basis, quarterly sales increased 5.4 percent compared to the same period in 2016. Fourth-quarter gross ma...

BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Laboratories, Inc. - June 2020 (LTM): Peer Snapshot

Peer Snapshot:  Bio-Rad Laboratories, Inc. - June 2020 (LTM) 9 September 2020 (in US millions) FYE Dec-18 FYE Dec-19 LTM Jun-20 FYE Dec-18 FYE Dec-19 LTM Jul-20 FYE Oct-18 FYE Oct-19 LTM Apr-20

BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Laboratories, Inc.: Update to credit analysis - Strong financi...

Bio-Rad will continue to operate with prudent financial policies and low financial leverage over the next 12-18 months despite coronavirus headwinds. But M&A could accelerate.

BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Laboratories, Inc. - March 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BIO Bio-Rad Laborat... (Health Care)

Moody's announces completion of a periodic review of ratings of Bio-Ra...

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc.. Global Credit Research- 15 May 2020. New York, May 15, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Bio-Rad Laboratories, Inc. and other ratings that are associated with the same analytical unit.

BIO Bio-Rad Laborat... (Health Care)

Bio-Rad Laboratories, Inc. - December 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BIO Bio-Rad Laborat... (Health Care)

Thanks to a better fundamental star rating, BIO-RAD LABORATORIES sees ...

The independent financial analyst theScreener just awarded an improved star rating to BIO-RAD LABORATORIES (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date April 9, 2021, the closing price was USD 602.57 and its expected value was estimated at USD 582.39.

BIO Bio-Rad Laborat... (Health Care)

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch